MyMedR

Displaying all 4 publications

Abstract:

Sort:

Fulltext Risk Analysis Characterization of Benzene and Demographic Factors toward Immunoglobulin A

Tualeka AR, Jalaludin J, Salesman F, Wahyu A, Tukiran T, Setiawan S, et al.

Open Access Maced J Med Sci, 2018 Dec 20;6(12):2381-2385.
PMID: 30607197 DOI: 10.3889/oamjms.2018.488

BACKGROUND: Research on risk assessment at industrial sites has experienced growth during the end of this year. But in Indonesia, there is still limited research on risk assessment, especially regarding the importance of measuring non-carcinogenic risk assessment in the workplace. Benzene exposure is believed to reduce levels of immunoglobulin A (IgA) in workers.
AIM: The purpose of this study was to analyse the relationship between risk quotient (RQ) of non-carcinogenic risk assessment of benzene and demographic factors on IgA levels.
MATERIAL AND METHODS: The subjects of the study were shoe craftsmen who were at risk of benzene exposure. The study design was cross-sectional with a total population of 20 workers. Measurement of IgA levels by Immunoturbidimetric Assay with a normal standard of 2-3 mg/ml. Calculation of non-carcinogenic (RQ) risk characteristics with a comparison between risk agent non-carcinogenic intake with RfD or RfC benzene.
RESULTS: The majority of the study subjects aged over 45 years and had a working period of ≥ 25 years. There were 2 location points that had a threshold value exceeding the benzene standard (> 0.05 ppm), and 40% of the subjects had decreased IgA levels. Age and working periods had a significant relationship to IgA levels (p = 0.027; p = 0.047), while benzene and RQ levels did not have a significant relationship with IgA levels (p = 0.179; p = 0.436).
CONCLUSION: Increasing age and working period can reduce IgA levels in the body. Further research is needed on risk assessment, especially on the safe limits of benzene concentration in the workplace to find out how long benzene exposure forms a non-carcinogenic or carcinogenic risk in workers' bodies exposed to benzene.
Fulltext Relationship of Benzene Concentration, ECR Benzene, Malondialdehyde, Glutathione, and DNA Degeneration in Shoe Industrial Workers in Osowilangun, Indonesia

Tualeka AR, Guan NY, Russeng SS, Ahsan A, Susilowati IH, Rahmawati P, et al.

Dose Response, 2020 06 26;18(2):1559325820921023.
PMID: 32636718 DOI: 10.1177/1559325820921023

In the shoes industry, benzene constitute as one of the source of chemical hazard especially used in the gluing section. This compound is metabolized by the liver, forming free radicals in the body which can ultimately reduce the concentration of glutathione and increased malondialdehyde causing DNA degeneration. The purpose of this study was to determine the relationship between benzene concentration, excess cancer risk (ECR), malondialdehyde, glutathione, and DNA degeneration among workers in shoes industry in Osowilangun, Surabaya. This is an observational study with a cross-sectional design. The number of research samples was 25 respondents. The average concentration of benzene in workers was above the threshold (10.31 ppm). There were 15 (60%) respondents with ECR >0.0001 who experienced DNA degeneration. There was no relationship between benzene concentration, malondialdehyde, glutathione, and DNA degeneration. However, there was a relationship between benzene ECR, malondialdehyde, glutathione, and DNA degeneration in the shoe industry workers in Osowilangun.
Phytochemical quantification and HPLC analysis of Parkia speciosa pod extract

Cheong NDH, Mohamed E, Haron N, Camalxaman SN, Abdullah A, Mohamad Yusof MI, et al.

Med J Malaysia, 2024 Mar;79(Suppl 1):34-39.
PMID: 38555883

INTRODUCTION: Parkia speciosa Hassk., commonly known as bitter bean or twisted cluster bean, is a tropical leguminous plant species native to Southeast Asia. The plant's edible pods have been traditionally used in various cuisines, particularly in Malaysian, Thai, and Indonesian cooking. Apart from being used as a food ingredient, the pods of P. speciosa also have a range of potential applications in other fields, including medicine, agriculture, and industry. The pods are said to have several phytochemicals that hold great therapeutic values such as reducing inflammation, improving digestion, and lowering blood sugar levels. However, there is limited information on the specific phytochemical contents of the pods in the literature. Thus, the aim of this study is to quantify the total phenolic and flavonoid compounds and to determine the concentrations of four selected phytochemical compounds in the P. speciosa pod extract (PSPE).
MATERIALS AND METHODS: Quantification of the total phenolic (TPC) and flavonoid contents (TFC) in PSPE were done via colourimetric methods; and the determination of the concentrations of four specific phytochemicals (gallic acid, caffeic acid, rutin, and quercetin) were done via High- Performance Liquid Chromatography (HPLC).
RESULTS: Colourimetric determination of PSPE showed TPC and TFC values of 84.53±9.40 mg GAE/g and 11.96±4.51 mg QE/g, respectively. Additional analysis of the phytochemicals using HPLC revealed that there were 6.45±3.36 g/kg, 5.91±1.07 g/kg, 0.39±0.84 g/kg, and 0.19±0.47 g/kg of caffeic acid, gallic acid, rutin, and quercetin, respectively.
CONCLUSION: The findings show that PSPE contains substantial amounts of caffeic acid, gallic acid, rutin, and quercetin, which may indicate its potential as antibacterial, anti-inflammatory, anti-lipid, and antiviral medicines.
Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023

GBD 2023 LDL Cholesterol Collaborators, Razo C, DeCleene NK, Johnson CO, Stark BA, LeGrand K, et al.

JAMA, 2026 Aug 25;336(8):673-698.
PMID: 42525403 DOI: 10.1001/jama.2026.8628

IMPORTANCE: Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C-related burden is critical for guiding prevention and treatment strategies.
OBJECTIVES: To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends.
DESIGN, SETTING, AND POPULATION: This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals.
EXPOSURE: Population-level LDL-C concentrations.
MAIN OUTCOMES AND MEASURES: Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C-attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals.
RESULTS: In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C-attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings.
CONCLUSIONS AND RELEVANCE: Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.